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Abstract
Overexpression of Dual-specificity tyrosine-phosphorylated regulated kinase 1A
(DYRK1A), located on human chromosome 21, may alter molecular processes
linked to developmental deficits in Down syndrome (DS). Trisomic DYRK1A is
a rational therapeutic target, and although reductions in Dyrk1a genetic dosage
have shown improvements in trisomic mouse models, attempts to reduce
Dyrk1a activity by pharmacological mechanisms and correct these DS-asso-
ciated phenotypes have been largely unsuccessful. Epigallocatechin-3-gallate
(EGCG) inhibits DYRK1A activity in vitro and this action has been postulated
to account for improvement of some DS-associated phenotypes that have been
reported in preclinical studies and clinical trials. However, the beneficial effects
of EGCG are inconsistent and there is no direct evidence that any observed
improvement actually occurs through Dyrk1a inhibition. Inconclusive outcomes
likely reflect a lack of knowledge about the tissue-specific patterns of spatial
and temporal overexpression and elevated activity of Dyrk1a that may con-
tribute to emerging DS traits during development. Emerging evidence indicates
that Dyrk1a expression varies over the life span in DS mouse models, yet pre-
clinical therapeutic treatments targeting Dyrk1a have largely not considered
these developmental changes. Therapies intended to improve DS phenotypes
through normalizing trisomic Dyrk1a need to optimize the timing and dose of
treatment to match the spatiotemporal patterning of excessive Dyrk1a activity
in relevant tissues. This will require more precise identification of developmen-
tal periods of vulnerability to enduring adverse effects of elevated Dyrk1a, rep-
resenting the concurrence of increased Dyrk1a expression together with
hypothesized tissue-specific-sensitive periods when Dyrk1a regulates cellular
processes that shape the long-term functional properties of the tissue. Future
efforts targeting inhibition of trisomic Dyrk1a should identify these putative
spatiotemporally specific developmental sensitive periods and determine
whether normalizing Dyrk1a activity then can lead to improved outcomes in
DS phenotypes.
Introduction
Trisomy of human chromosome 21 (Hsa21) results in
myriad phenotypes including cognitive impairment, car-
diac abnormalities, and craniofacial features collectively
referred to as Down syndrome (DS) (OMIM: 190685).
Worldwide, DS affects 1 in 700–1000 live births (Parker
et al. 2010). In nearly all cases of DS, three copies of
~300 genes found on Hsa21 occur in every cell beginning
at conception and affect developmental processes in every
system of the body. Phenotypes related to Trisomy 21
(Ts21) are apparent before birth and continue into old
age. How three copies of genes on Hsa21 cause the phe-
notypes of DS is largely unknown. Although it has been
assumed that trisomic genes are expressed at the dosage
corresponding to chromosomal material in the cell (1.5
times that of normal, disomic genes) (Potier et al. 2006;
Liu et al. 2008), multiple genetic mechanisms have been
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suggested for how the dosage imbalance of trisomic genes
cause DS phenotypes (Potier et al. 2006; Roper and
Reeves 2006; Antonarakis 2017). Hypothesized alternative
mechanisms include suggestions that some trisomic genes
or regions may be dosage sensitive and have a large effect
on a particular DS phenotype, that trisomy globally alters
gene expression throughout the genome, and that trisomy
affects chromatin function (Roper and Reeves 2006; Kor-
bel et al. 2009; Lyle et al. 2009; Ahmed et al. 2012;
Letourneau et al. 2014; Antonarakis 2017). Owing largely
to advances and applications in mouse models, the
administration of therapies targeting phenotypes associ-
ated with DS has grown substantially over the past
15 years and have targeted diverse mechanisms (Stagni
et al. 2015). To date, there have been over 20 different
potential treatments administered to DS model mice in
preclinical studies evaluating cognitive and behavioral
phenotypes, with many treatments reporting improved
phenotypes or symptoms observed in DS via targeting
either specific neurotransmitter systems or aberrant neural
pathways [for extensive review see (Gardiner 2015)].
Although a single trisomic genetic region or gene is
not responsible for all DS phenotypes, there may be genes
that have a major influence on phenotype(s) associated
with DS due to the overexpression of a trisomic gene
(Olson et al. 2004; Liu et al. 2008; Korbel et al. 2009; Lyle
et al. 2009). One such gene, Dual-specificity tyrosine-phos-
phorylated regulated kinase 1A, is located on Hsa21
(DYRK1A) (OMIM: 60085), and mouse chromosome
(Mmu)16 (Dyrk1a), and its overexpression has been
linked to brain pathology in humans with DS and DS
animal models (Dowjat et al. 2007; Liu et al. 2008). Con-
sequently, Dyrk1a has been identified as a target for ther-
apeutic drug development in DS (de la Torre and
Dierssen 2012; Duchon and Herault 2016). Less consider-
ation has been given, however, to when and where the
trisomic gene is overexpressed, and whether that spa-
tiotemporal regulation is causally related to the develop-
ing phenotype. Furthermore, many studies assessing
therapeutics of Dyrk1a inhibition do not take into con-
sideration the spatiotemporal regulation of the expression
of Dyrk1a when administering Dyrk1a inhibitors to
mouse models in DS. Consequently, few studies that
administer Dyrk1a inhibitors (such as Epigallocatechin-3-
gallate [EGCG]) directly examine concurrent Dyrk1a
expression levels or the correlation between reduced
Dyrk1a activity and therapeutic efficacy. This review
examines the possible contributions of trisomic Dyrk1a to
DS cognitive phenotypes, identifies major gaps in evi-
dence needed to ascertain its putative role, and proposes
a general strategy for developing rational treatments
targeting trisomic genes to improve the developmental
trajectory of DS.
The Role of DS Mouse Models in
Finding Therapies
Because of regions of homology between Hsa21 and
Mmu16, Mmu17, and Mmu10 (Pletcher et al. 2001), vari-
ous DS mouse models have been created [reviewed in
(Das and Reeves 2011; Gupta et al. 2016; Xing et al.
2016)]. The use of mouse models with Hsa21 homolo-
gous genes in three copies has advanced efforts to corre-
late trisomic genes or regions with DS-associated
phenotypes. The Ts65Dn model consists of a segmental
trisomy of Mmu16 that contains approximately 50% of
the gene homologs found on Hsa21 (Davisson et al.
1990), and is the model used most often to test treat-
ments to improve the various deficits observed in DS
(Gardiner 2015). Successful outcomes from mouse models
of DS have progressed to human clinical trials, due to the
similarities in genetics (construct validity), particular phe-
notypes that are displayed (face validity) and new knowl-
edge that may be applied to humans (predictive validity)
(Rueda et al. 2012). However, results from large-scale
clinical settings have been generally disappointing. Lack
of translational success from preclinical models to clinical
trials is hardly unique to DS (Garner et al. 2017). Overall,
there is a high failure rate (>80%) of clinical trials devel-
oped from preclinical findings in various mouse models
of diseases (Gupta et al. 2016). Nevertheless, preclinical
models of DS are likely essential for therapeutic advances,
and it is critical to assess the rationale and mechanisms of
targeted therapeutics in these mouse models because they
provide the scientific and empirical foundation for clinical
trials.
Many DS-related approaches have largely focused on
improving the phenotypes observed in DS. An alternative
approach is to understand the influence of a trisomic
gene product suspected to have a significant causative
effect on the development of a phenotype and its aberrant
mechanism, and develop treatments targeting those mech-
anisms (Ahmed et al. 2012). Therapeutics based on nor-
malization of a single gene on an otherwise trisomic
background to correct DS phenotypes is a significant
paradigm shift, and has been supported by evidence from
trisomic mouse models in which the normalization of
one or two trisomic genes on an otherwise trisomic back-
ground from conception corrected some DS phenotypes
(Cataldo et al. 2003; Hill et al. 2009; Chakrabarti et al.
2010; Blazek et al. 2015; Jiang et al. 2015; McElyea et al.
2016; Kleschevnikov et al. 2017). The role of trisomic
Dyrk1a in pathology associated with DS has been sup-
ported by the numerous reports of deleterious phenotypes
that occur due to both over and underexpression of
Dyrk1a in transgenic Dyrk1a mouse models (Arque et al.
2013) (see Table S1). Furthermore, Dyrk1a appears to
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have a crucial role during central nervous system develop-
ment (CNS), via its regulation of multiple targets in both
the nucleus and the cytoplasm via phosphorylation [ex-
tensively reviewed in (Becker et al. 2014; Duchon and
Herault 2016)]. Normalization of Dyrk1a copy number in
otherwise trisomic mouse models has resulted in some
improvements in cognitive and behavioral phenotypes
(Garcia-Cerro et al. 2014).
Several recent reviews have discussed in detail the
numerous targets of Dyrk1a, and have suggested how
molecular mechanisms altered by excessive Dyrk1a could
affect cognitive and behavioral processes (Wegiel et al.
2011; Park and Chung 2013; Duchon and Herault 2016;
Antonarakis 2017). In addition, several reports have
described potential Dyrk1a inhibitors and their possible
use for correcting DS-related deficits (de la Torre and
Dierssen 2012; Becker et al. 2014; Duchon and Herault
2016). The present review extends those recent analyses
by emphasizing an additional but crucial aspect of the
therapeutic potential of Dyrk1a inhbition for DS – the
importance of understanding when and where Dyrk1a
expression and activity is elevated and determining
whether some periods of elevated Dyrk1a may represent
sensitive periods of developmental vulnerability for estab-
lishing long-lasting DS structural and functional pheno-
types. As a corollary, this review critically evaluates the
literature on treatments using pure EGCG and EGCG-
containing supplements (the most frequently used puta-
tive Dyrk1a inhibitor to date) in DS mouse models,
pointing to current limitations and additional informa-
tion that is still needed to establish the full therapeutic
potential of Dyrk1a inhibition.
Function and Expression of Dyrk1a in
Rodent Models
The expression of Dyrk1a mRNA and/or protein during
normal (nontrisomic) development may provide insight
into how overexpression of this kinase may lead to
deleterious phenotypes. Dyrk1a is highly expressed dur-
ing normal embryonic development, specifically in
regions of the developing CNS (Martı́ et al. 2003;
H€ammerle et al. 2008). The impact of Dyrk1a dosage
alterations during development has been demonstrated
in early studies reporting the embryonic lethality of
knocking out Dyrk1a completely, with ~80% of
homozygous Dyrk1a knockout mice (KO) dying in utero
between Embryonic day (E)10.5–E13.5, and none sur-
viving postnatally. Mice with only one copy of Dyrk1a
present growth retardations and neurological deficits
(Fotaki et al. 2002). Widespread expression of Dyrk1a
protein was found in E17 mouse embryos and adult
mice, but it was reported to be more abundant in
regions of the CNS, specifically the cerebral cortex,
cerebellum and hippocampus (Rahmani et al. 1998).
Thus, while Dyrk1a protein may be ubiquitously
expressed, there may be varying levels of protein within
a specific tissue. This hypothesis is supported by the
finding that levels of Dyrk1a protein expression in adult
mice (aged 6 months–1 year) vary across different brain
regions, with significantly higher Dyrk1a protein expres-
sion in the olfactory bulb and cerebellum compared to
the cerebral cortex, hippocampus and hypothalamus
(Martı́ et al. 2003). In addition, an extensive analysis of
both Dyrk1a mRNA and protein expression during
embryonic development revealed that expression of both
mRNA and protein is dependent on spatial and tempo-
ral factors (H€ammerle et al. 2008).
While some studies report strong correlations between
Dyrk1a mRNA and Dyrk1a protein levels across multiple
tissues (H€ammerle et al. 2008), there can be mismatches
in the level of gene expression and protein levels across
time. For instance, during early postnatal development in
Wistar rats (Postnatal day (P)1-P21), Dyrk1a mRNA
expression assessed via Northern blot was low in the cere-
bellum, whereas Dyrk1a protein expression assessed via
Western blot was highest during these same time points.
Later in development (P21-adulthood), Dyrk1a mRNA
expression in the cerebellum was high, and protein
expression was reduced (Okui et al. 1999). Thus,
although Dyrk1a mRNA expression may be prevalent
throughout the brain, there can be significant differences
in the regulation of gene expression and in the levels of
protein, even within specific brain regions (Table S2).
While there has not been a systemic analysis of both
Dyrk1a mRNA and protein expression levels in the
Ts65Dn mice, it is critical to note that mRNA/protein
expression in trisomic humans and mice does not always
follow the theoretical 1.5-fold overexpression (Lockstone
et al. 2007). Varying levels of Hsa21 gene dysregulation
have been reported in both human and mouse tissue, and
the degree of over or underexpression may depend on the
age, as well as the type of tissue being sampled (Chrast
et al. 2000; Bahn et al. 2002; Mao et al. 2003; Chou et al.
2008; Vilardell et al. 2011). For example, there were no
reported differences in Dyrk1a mRNA levels between
Ts65Dn and euploid mice at 5 months of age, but at
12 months of age Ts65Dn mice exhibited elevated levels
compared to euploid animals (Choi et al. 2009). In addi-
tion, although Dyrk1a protein levels were significantly
increased in three distinct brain regions in adult Ts65Dn
mice, there was not the theoretical 50% increase in the
hippocampus or cerebellum (31% and 24% increased,
respectively) (Ahmed et al. 2012).
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Dissecting the Functional Role of
Dyrk1a from Humans with Partial
Trisomy and in Trisomic Mouse
Models
Studies in humans and mice have attempted to correlate
specific trisomic genes or regions and DS phenotypes.
Although a single gene or genetic region is not responsi-
ble for all DS phenotypes (Lyle et al. 2004; Olson et al.
2004; Korbel et al. 2009), unraveling the contribution of a
single trisomic gene such as DYRK1A has been compli-
cated. In humans, trisomy of DYRK1A in isolation has
not been reported, and therefore its singular effects on
trisomic phenotypes may be underestimated (see the
DYRK1A triplosensitivty score of 0 from the ClinGen
Working Group Dosage Sensitivity Map [https://www.ncb
i.nlm.nih.gov/projects/dbvar/clingen/clingen_gene.cgi?sym
=DYRK1A&subject=]). Trisomy of only DYRK1A may be
lacking due to limitations of recombination or detection
in humans. Trisomic DYRK1A has been found in
humans with partial trisomy of Hsa21 and trisomic
regions including DYRK1A have been associated with DS
phenotypes (Korbel et al. 2009; Lyle et al. 2009; Cetin
et al. 2012; Papoulidis et al. 2014). From these data, it
may be that DYRK1A may exert its deleterious effects in
conjunction with other triplicated genes. Thus, inhibition
of just DYRK1A may not completely improve a DS-
related phenotype. In addition, this could also suggest
that the DYRK1A overexpression, and its deleterious
effects may be specific to a defined window of develop-
ment, and a specific tissue.
Transgenic Dyrk1a mouse models (on an otherwise
euploid background) have provided information regard-
ing the deleterious effects of overexpression of Dyrk1a
itself (Table S1), but have some genetic caveats to under-
standing the function of Dyrk1a. It is important to note
that there is variability in specific phenotypes of trans-
genic Dyrk1a mouse models, for example in motor devel-
opment/performance. This could be due to differences in
the behavioral tasks used to measure this phenotype, such
as gait assessment, latency to begin walking, balance beam
task, and various rotarod tasks. In addition, differences
observed between transgenic Dyrk1a mice could be due to
biological variations in the specificity of spatial expression
of Dyrk1a between transgenic models, as different trans-
genic models express Dyrk1a under different promoters
(Altafaj et al. 2001; Ahn et al. 2006). The age of assess-
ment may also play a role in the differences between
studies. For example, BACTgDyrk1a as compared to con-
trol mice exhibit decreased body weight and length on
P30, but these same measures are not significantly differ-
ent at P15 and P60 (Guedj et al. 2012). TgDyrk1a mice,
one of the most utilized Dyrk1a transgenic models, appear
to display age-specific deficits on multiple developmental
assessments, including walking, pivoting locomotion, and
negative geotaxis (Arque et al. 2013). Interestingly,
YACTgDyrk1a are not impaired on the Y-maze task,
which is thought to measure spatial working memory,
whereas the BACTgDyrk1a mice are impaired, even
though the mice were approximately the same age
(~3 months) in comparative studies (Guedj et al. 2009;
Souchet et al. 2014). The age and phenotype-dependent
differences evident in these mice suggest that the deleteri-
ous effects of Dyrk1a overexpression could depend on
certain age(s), tissue(s), and means of phenotypic
assessment.
Transgenic Dyrk1a mouse models are limited as models
of DS because there are multiple genes that are dysregu-
lated in DS, not just Dyrk1a. Consequently, a phenotype
that is observed in Dyrk1a transgenic mice may have lim-
ited validity as a DS model and may not translate to a tri-
somic mouse model with many trisomic genes in three
copies, due to the lack of interactions with other overex-
pressed or trisomic genes or differences in developmental
trajectories between trisomic mice compared to Dyrk1a
transgenic mice. In turn, other triplicated genes that are
observed in trisomic models can make it difficult to
understand the independent contribution of Dyrk1a over-
expression to a specific phenotype in the Ts65Dn mouse.
If the polygenic trisomic contributions are not under-
stood, it would be difficult to develop a targeted thera-
peutic based on improvements in one or even multiple
behavioral outcomes. While Dyrk1a transgenic mice high-
light the importance of regulated Dyrk1a expression dur-
ing development, studies of mouse models that are
trisomic for Dyrk1a in conjunction with other Hsa21
homologous genes are crucial to better understand
Dyrk1a expression and its association with DS traits.
Ts65Dn mice, with Dyrk1a and approximately 100
other genes in three copies, display some similar cognitive
and behavioral deficits as transgenic Dyrk1a mice. With
the triplication of many genes, it is important to deter-
mine the direct influence of Dyrk1a overexpression on
Ts65Dn trisomic phenotypes. In contrast to mice only
overexpressing Dyrk1a, or Ts65Dn mice that are trisomic
for many genes, Ts65Dn mice crossed with Dyrk1a hap-
loinsufficient mice, result in some Ts65Dn mice with a
normalized copy number of Dyrk1a (Ts65Dn/Dyrk1a
+/+/) on an otherwise trisomic background (Garcia-
Cerro et al. 2014; Blazek et al. 2015; McElyea et al. 2016).
This gold standard methodology is used to understand
the behavioral phenotypes that are improved in Ts65Dn/
Dyrk1a +/+/ mice versus Ts65Dn/Dyrk1a +/+/+
(Ts65Dn) mice, which could be specifically attributed to
the extra copy of Dyrk1a on a trisomic background
(Table 1). Male Ts65Dn/Dyrk1a +/+/- mice (6–7 months
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old) exhibited a partial improvement in MWM latency,
neuronal proliferation and differentiation, and hippocam-
pal LTP. However, there were several phenotypes that
were not rescued with normalization of Dyrk1a levels,
including cell density of mature neurons in the dentate
gyrus, dentate gyrus volume, or a variety of motor task
deficits (Garcia-Cerro et al. 2014). Subtracting one copy
of Dyrk1a from another DS mouse model, Dp(16), (over
half of the homologous genes on Hsa21 in three copies)
showed that Dp(16) mice with one fewer copy of Dyrk1a
performed better on T-maze and contextual fear condi-
tioning tests as compared to Dp(16) mice (Jiang et al.
2015). The lack of rescued motor task deficits is interest-
ing, as administration of an adeno-associated virus type 2
(AAVshDyrk1a) into the striatum lowering expression of
Dyrk1a in TgDyrk1a mice normalized motor task deficits
(Ortiz-Abalia et al. 2008). A similar viral technique in 2-
month-old Ts65Dn mice restored LTP deficits and nor-
malized Dyrk1a protein levels in the hippocampus, but
did not rescue MWM latency deficits (Altafaj et al. 2013).
As with transgenic Dyrk1a animals, strain, methodological
differences in the various tasks, or differences in the age
of the subjects may account for outcome differences
between studies (Table 1). Taken together, normalization
of Dyrk1a does not appear to be responsible for all the
deficient cognitive and behavioral phenotypes of trisomic
mice. Thus, the influence of Dyrk1a on a specific pheno-
type in trisomic mice is complex, and other trisomic
genes likely contribute to these phenotypes.
In addition, it is likely that Dyrk1a’s overexpression
and subsequent influence could be strongest at a specific
developmental time (for a given tissue) when develop-
mental trajectories are established for the tissue. If so,
then normalizing or reducing this overexpression at a
specific time (for that tissue) may produce an optimal
timing for a potential therapeutic. Although genetic
reductions of Dyrk1a copy number from conception have
shown significant corrections of DS phenotypes (Garcia-
Cerro et al. 2014; Blazek et al. 2015; Jiang et al. 2015;
McElyea et al. 2016), and provide proof-of-principle that
Dyrk1a is a relevant target, pharmacological treatments
targeting Dyrk1a activity to date have had only limited
successes due to a limited understanding of the effects of
spatial and temporal overexpression of trisomic Dyrk1a.
Unresolved Questions about Dyrk1a
If a treatment is to target Dyrk1a overexpression for defi-
cits observed in Ts21, several important questions need to
be addressed. First, the levels of Dyrk1a protein and kinase
activity in Ts65Dn mice throughout development need to
be ascertained; these levels are not well known, especially
during perinatal and young adolescent stages (Table 2).
This emphasizes the need to identify and understand the
temporal and spatial regulation of Dyrk1a expression in
trisomic mice, especially considering suggestions of the
prenatal or neonatal developmental age as an optimal tar-
get window for improving deficits in DS (Guedj et al.
2014; Stagni et al. 2015). A recent study showed that the
magnitude of protein abnormalities of both Hsa21 and
non-Hsa21 proteins were exacerbated in 12-month-old
Ts65Dn mice versus ~6-month-old Ts65Dn mice (Ahmed
et al. 2017). Specifically, in the hippocampus of Ts65Dn
mice, Dyrk1a protein levels were only 30% higher than
controls at 6 months of age, but these levels were 100%
higher in the 12-month-old Ts65Dn mice, versus euploid
controls (Ahmed et al. 2017). Temporal regulation of
Dyrk1a protein levels has also been reported in the Ts1Cje
Table 1. The effects of normalizing Dyrk1a copy number in TgDyrk1a and Ts65Dn mice.
Mouse
model Technique Age Area Improved Did not improve Authors
Ts65Dn shRNA 2 month Hippocampus LTP, initial thigmotaxic
behavior
MWM latency, later
thigmotaxic behavior
Altafaj et al. (2013)
TgDyrk1a shRNA 2–3 month Striatum Hyperactive behavior,
treadmill task, PPI
N/A Ortiz-Abalia et al.
(2008)
Dp16 Crossed with
Dyrk1a m1/+ mice
2–4 month Global T-maze task, contextual
fear conditioning
N/A Jiang et al. (2015)
Ts65Dn Crossed with
Dyrk1a +/ mice
5–6 month Global Some MWM latency, LTP,
neuronal proliferation
& differentiation
Fear conditioning,
motor coordination,
locomotor activity,
open field anxiety, cell
survival, DG volume,
SGZ area, body weight
Garcia-Cerro et al. (2014)
MWM, Morris water maze; LTP, long-term potentiation; PPI, prepulse inhibition; DG, dentate gyrus; SGZ, subgranular zone; N/A, not available or
done.
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mouse model in the cerebellum at three adult ages. Dyrk1a
protein levels significantly increased with age in adult
Ts1Cje mice (between 4, 12, and 17 months of age)
(Creau et al. 2016). In embryonic day (E) 13.5 Ts1Cje
embryos, there was increased Dyrk1a protein expression in
cortical neurons. However, in whole brains of E11.5
Ts1Cje embryos and in hippocampal neurons of P1
Ts65Dn mice, there were no differences in levels of Dyrk1a
protein (Arron et al. 2006). In addition, Dyrk1a protein
expression in Ts65Dn mice at ~68 days of age did not
show differences in protein expression between euploid
and trisomic mice in the hippocampus or cerebral cortex.
However, trisomic mice at this same age exhibited an
unexpected significant decrease in Dyrk1a protein levels in
the cerebellum (Stringer et al. 2017). Finally, expression of
Dyrk1a protein itself may not be sufficient to identify its
role in development, since its kinase activity may be the
most proximal measure of its regulation of cellular
dynamics. Overall, the influence of Dyrk1a is likely to be
dependent on both spatial and temporal factors.
A second factor that needs to be addressed is the tis-
sue and cellular specificity of Dyrk1a expression levels in
trisomic mice. This is crucial to link the tissue specificity
and timeline of overexpression of Dyrk1a to a specific
phenotype. Patterns of age-dependent structural and his-
tological phenotypes that vary with brain region are now
recognized (see Table S3 [cerebellum] and Table S4
[hippocampal formation]). Yet, the lack of systematic
quantitative data for Dyrk1a protein and/or mRNA levels
in specific tissues makes it difficult to fully ascertain the
role of Dyrk1a in the development of a specific pheno-
type. For example, Dyrk1a may have been overexpressed
earlier in development that preceded or led to the phe-
notypic changes in the cerebellum evident at a later age.
As another example, it is reasonable to hypothesize that
MWM deficits reported in some studies of trisomic mice
would be associated with a concomitant elevation in
Dyrk1a in the hippocampus at the age of testing (Gar-
cia-Cerro et al. 2014; de la Torre et al. 2014; Stringer
et al. 2015; Stringer et al. 2017). If so, this could directly
implicate Dyrk1a overexpression in the hippocampus for
MWM deficits and provide a means to test correlations
between Dyrk1a activity and cognitive therapeutics with
inhibitors. These examples highlight the need to identify
whether overexpression of Dyrk1a at the time of behav-
ioral testing is associated with a given phenotype, or
identify whether a period of overexpression earlier in
development (that subsequently resolved prior to testing)
may be associated with the deficient phenotype. Because
the influence of Dyrk1a overexpression on particular
phenotypes appears to be dependent on age, it will be
important to establish the developmental periods during
which Dyrk1a is overexpressed and the specific brain sys-
tems in which it occurs, before causal links to the speci-
fic structural and behavioral phenotypes can be inferred.
More detailed studies of these spatio-temporal differ-
ences in Dyrk1a expression and activity are a prerequi-
site to identify an appropriate therapeutic window to
target.
It will also be important to address how the expression
of Dyrk1a during a developmental process directly results
in a specific behavioral phenotype. For example, the rela-
tionship between Cyclin D1 and Dyrk1a is an attractive
mechanism because Cyclin D1 and Dyrk1a protein levels
have been reported in Ts65Dn mice at a specific age and
region (Najas et al. 2015). Dyrk1a protein levels were sig-
nificantly increased in E11.5 Ts65Dn mice, whereas Cyclin
D1 protein levels were significantly decreased. Documen-
tation of Dyrk1a protein levels in a specific tissue, com-
bined with known levels of a potential target in Ts65Dn
Table 2. Dyrk1a protein and kinase activity levels in various brain regions in Ts65Dn mice.
Age Area Effect Authors
E11.5 Telencephalon Increased Dyrk1a protein levels Najas et al. (2015)
1.5 month Cerebellum, hippocampus No difference in Dyrk1a kinase-related activity Stringer et al. (2015)
~2 month Cerebellum, cortex, hippocampus No difference in Dyrk1a kinase-related activity Stringer et al. (2017)
~2 month Cerebellum Ts65Dn mice exhibit decreased Dyrk1a protein
levels, no difference in cortex or hippocampus
Stringer et al. (2017)
3.5 month Hippocampus Increased Dyrk1a protein levels Altafaj et al. (2013)
4.4–7.8 month Cerebellum, cortex, hippocampus Increased Dyrk1a protein levels Ahmed et al. (2012)
5–6 month Hippocampus Increased Dyrk1a protein levels Garcia-Cerro et al. (2014)
~6 month Hippocampus, cortex, cerebellum Increased Dyrk1a protein levels Ahmed et al. (2017)
7–8 month Cortex, hippocampus Increased Dyrk1a protein levels Siddiqui et al. (2008)
7–8 month Brain homogenate Increased Dyrk1a protein levels Dowjat et al. (2007)
12 month Hippocampus, cortex, cerebellum Increased Dyrk1a protein levels Ahmed et al. (2017)
13–14 month Brain homogenate Increased Dyrk1a protein levels Kida et al. (2013)
15 month Brain homogenate Increased Dyrk1a protein and activity Liu et al. (2008)
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mice, is rare and could facilitate identification of the rela-
tionship between the level of Dyrk1a activity and a partic-
ular phenotype. For example, Dyrk1a directly regulates
Cyclin D1, and normalization of Dyrk1a expression
resulted in a rescue of both progenitor production and
neuronal differentiation (Najas et al. 2015).
The direct link of Dyrk1a overexpression to a specific
mechanism described above suggests that normalization
of Dyrk1a could lead to a rescue of a specific phenotype.
One hypothesis is that normalization of the embryonic
and postnatal cell cycle would result in an improved cog-
nitive-based task. It remains unknown whether correction
of a prenatal cellular phenotype, like embryonic progeni-
tor production or neuronal maturation, will correct defi-
cient postnatal phenotypes that subsequently emerge (like
LTP or spatial memory). Furthermore, whether a prenatal
treatment that corrects a developmental cellular or struc-
tural deficiency would also improve a postnatal behavioral
phenotype is still unknown. Given the importance of
Dyrk1a regulation of major neurodevelopmental pro-
cesses, and the distinct likelihood that the postnatal tra-
jectory of altered brain structural and functional
development in DS has its origins in fetal or postnatal
Dyrk1a overexpression, it is essential to identify the sub-
strates or secondary targets of Dyrk1a regulation that are
implicated in deleterious neurodevelopmental phenotypes.
For example, studies that normalized Dyrk1a levels at var-
ious ages in different strains of mice demonstrated that
the overexpression of this gene is implicated in motor, as
well as cognitive-based tasks such as the MWM (Ortiz-
Abalia et al. 2008; Altafaj et al. 2013; Garcia-Cerro et al.
2014). However, with the heterogeneity in mouse strains,
Dyrk1a normalization methodologies and the different
ages of the animals, it is difficult to ascertain what specific
phenotype(s) the Dyrk1a dosage imbalance is influencing.
Najas et al. (2015) demonstrated that the normalization
of Dyrk1a in Ts65Dn mice significantly improved embry-
onic neurogenesis deficits, and future studies should
examine whether this improved neurogenesis also results
in an improved behavioral phenotype.
EGCG and Dyrk1a Inhibition
DYRK1A has become a target for DS drug development
(Duchon and Herault 2016) and several molecules have
been identified or developed to inhibit DYRK1A activity,
including harmine, EGCG, INDY, FINDY, leucettine
L41and CX-4945 (Adayev et al. 2011; Ogawa et al. 2010;
Kii et al. 2016; Kim et al., 2016; Fant et al. 2014; Naert
et al. 2015). These molecules may have limited pharma-
cotherapeutic value due to side effects or off-target effects
[e.g., harmine has side effects associated with monoamine
oxidase A (MOA) inhibition (Kim et al. 1997)]. Others
have only recently been developed and have not under-
gone extensive preclinical testing.
One inhibitor of DYRK1A activity that has been exten-
sively used in preclinical and in human clinical studies is
EGCG. EGCG, the most common green tea polyphenol,
inhibits DYRK1A activity in vitro (Bain et al. 2003). A
relatively safe drug profile, combined with its ability to
inhibit DYRK1A in vitro, and the translational value of
comparative studies between animal models and clinical
settings, support the current enthusiasm for pursing
EGCG treatment to improve phenotypes observed in Ts21
(Bain et al. 2003; Adayev et al. 2006; Smith 2011).
Although EGCG was originally administered in the DS
setting for its ability to inhibit DYRK1A activity, the field
has largely failed to determine whether EGCG treatment
– usually administered as part of a supplement either to
trisomic mice or to individuals with DS – actually
improves the behavioral and cellular deficits via inhibition
of Dyrk1a activity, the putative mechanism of its effects.
Heterogeneity in Behavioral
Outcomes after EGCG and EGCG-
containing Supplement
Administration
Several studies that have administered EGCG or EGCG-
containing supplements to transgenic Dyrk1a or Ts65Dn
mice have reported improved behavioral outcomes
[Table 3, also see (Stagni et al. 2017)]. The amount of
heterogeneity among studies across multiple variables is
striking, involving different mouse models, ages, doses and
composition of the EGCG treatment, as well as different
behavioral tasks and outcomes. At a minimum, all studies
should control or monitor the amount and composition
of the EGCG treatment administered to the subjects and
identify the effective dose and levels of EGCG achieved in
the subjects over time. Many studies have used EGCG-
containing supplements as the source of EGCG, and there
are several supplements that contain additional compo-
nents such as other catechins, sucrose, and/or caffeine.
The other catechins found in EGCG-containing supple-
ments, such as epigallocatechin (EGC), epicatechin gallate
(ECG) epigallate (EG), and epicatechin (EC) could be act-
ing synergistically with EGCG, or could be exerting effects
independently of EGCG (Abeysekera et al. 2016). For
example, EGCG-containing supplements exhibit differen-
tial effects on various skeletal measures, with some supple-
ments improving trabecular structure, yet others being
detrimental to bone strength (Abeysekera et al. 2016). This
demonstrates that the other components of EGCG-con-
taining supplements may contribute to the variable out-
comes of treatment, depending on the specific phenotype
that is assessed. Before mechanistic interpretations can be
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inferred, it is imperative that the independent effect of
EGCG on Ts65Dn mice is evaluated.
Transgenic Dyrk1a mouse models (TgDyrk1a, BACTg-
Dyrk1a, YACTgDyrk1a) have been widely used to test
EGCG or EGCG-containing supplements, and all of these
studies have reported improved behavioral outcomes.
This is in stark contrast to our studies using Ts65Dn mice
that have reported minimal, null, or negative effects of
pure EGCG administration on cognitive outcomes (Strin-
ger et al. 2015, 2017). The genetic differences between
mouse models may underlie these discrepant results.
Looking across studies, the administration of Mega Green
Tea Extract (MGTE) Lightly Caffeinated (45% EGCG)
improved MWM and NOR deficits in both Ts65Dn and
TgDyrk1a mice (de la Torre et al. 2014). This treatment
reduced Dyrk1a kinase activity in TgDyrk1a animals, sug-
gesting that Dyrk1a overexpression and subsequent
increased kinase activity could be driving these behavioral
deficits in the transgenic mice. However, the same study
did not report the effect of this treatment on Dyrk1a
kinase activity in Ts65Dn mice. Thus, from this study, it
remains unknown whether Dyrk1a activity is correlated
with Ts65Dn behavioral deficits or improvement from
treatment with EGCG-containing supplements.
Pure EGCG Administration has Failed
to Reduce Dyrk1a-related Kinase
Activity In Vivo
There are only a few studies that have administered
EGCG in vivo and reported effects on Dyrk1a kinase
levels [Table 3]. A crucial gap in current research is that
a decrease in Dyrk1a kinase activity in Ts65Dn mice (with
more than Dyrk1a at dosage imbalance) has not been
specifically attributed to EGCG. Reduced Dyrk1a kinase
activity was shown in the hippocampus of young adult
transgenic TgDyrk1a male and female mice following
administration of an EGCG-containing supplement (Mega
Green Tea Extract- 45% EGCG, 98% polyphenols) (Pons-
Espinal et al. 2013; de la Torre et al. 2014). However,
until experimental studies in trisomic mouse models
demonstrate the extent, duration, and dose-dependency
of inhibition of Dyrk1a by EGCG in specific brain regions
(or other tissues) that is directly linked to improved phe-
notypes, there will be uncertainty as to whether EGCG
inhibition of Dyrk1a can account mechanistically for any
therapeutic outcomes. Future studies need to identify
when and where Dyrk1a overexpression occurs in tri-
somic mice, and show that EGCG normalizes Dyrk1a
kinase activity at relevant times in relevant brain regions.
Some contravening in vivo data in mice challenge the
hypothesis that EGCG inhibits brain Dyrk1a activity to
improve functional outcomes. For example, using a
radioactive-based assay, no significant differences in
Dyrk1a-related kinase activity levels were seen between
euploid and Ts65Dn mice at 6 weeks of age, nor did
EGCG treatment have an effect on these levels (Stringer
et al. 2015). Several studies have reported methodological
variations of Dyrk1a kinase assays (de la Torre et al.
2014; Stringer et al. 2015, 2017), and it will be important
to further develop these assays in trisomic mouse models,
as well as determining their specificity. In addition, fur-
ther exploration into potential biomarkers, such as the
plasma biomarker homocysteine (Hcy), should be exam-
ined as a potential measurement of treatment efficacy
(Noll et al. 2009; de la Torre et al. 2014). Increased
Dyrk1a protein levels in the liver of Ts65Dn mice have
been correlated with decreased levels of plasma Hcy (Noll
et al. 2009). In addition, there is a significant correlation
between increased levels of Dyrk1a protein in the brain,
and decreased levels of Hcy. Although 1 month of treat-
ment with an EGCG-containing supplement normalized
plasma Hcy levels (de la Torre et al. 2014), it is unsure if
these changes in Hcy levels are directly linked to changes
in Dyrk1a activity. Future studies should determine
whether alternate Dyrk1a inhibitors affect Hcy levels, in
addition to determining if age of the mice affects the rela-
tionship between Dyrk1a protein levels and Hcy levels.
There is not a Consistent Dose/Route
of EGCG Administration to Inhibit
Dyrk1a Activity
The dose and route of EGCG administration is also
highly variable across studies. Calculations of the amount
of EGCG administered in any dosing regimen must
account for the differences in the amount of EGCG in the
various EGCG-containing supplements used, and should
also determine the amount of the other catechins
included in those supplements. The route of administra-
tion can also critically determine the amount of EGCG
delivered to the tissue. When studies differ in the routes
of administration, the temporal profile of EGCG levels
reached in various tissue compartments and the within-
day variation in those levels is a key issue. The amount of
EGCG delivered to the subject may either be directly con-
trolled either by the experimenter (e.g., gavage or injec-
tion) or by the subject (oral consumption in the drinking
water). Many studies administer EGCG via the drinking
water, and the average intake is usually recorded over
days to determine the average EGCG consumption. When
EGCG delivery is controlled by the daily pattern of fluid
consumption of the mouse, the levels of EGCG in the
blood and tissues are difficult to establish or monitor,
and will vary dramatically over the day by factors inher-
ent to the subjects, including circadian regulation of
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drinking and pharmacokinetic differences in EGCG
absorption, distribution, and metabolism. With this route
of administration, EGCG levels in the tissues, if they do
reach measurable levels, will vary substantially over time,
but this source of variation is generally not accounted for
or monitored when behavioral or biological endpoints are
obtained. Another source of uncertainty about the dosage
of EGCG is its instability in solution. EGCG undergoes
rapid degradation in water, and solutions made from
95% EGCG lose approximately 80% of their initial con-
centration after just 48 hours. Acidifying the water by
addition of phosphoric acid (approximately 100 lL/
100 mL tap water) to EGCG solutions has been shown to
stabilize EGCG and limit degradation to approximately
50% after 48 hours. This acidification has no effect on
fluid consumption in the mice, thereby effectively increas-
ing the daily amount of EGCG delivered via the drinking
water (Stringer et al. 2015). All studies involving EGCG
administration via the drinking water, whether of EGCG
alone or of EGCG-containing supplements, must account
for degradation when calculating the daily dose of EGCG
that animals receive.
The pharmacokinetics of EGCG need to be considered
when deciding on a dose or route of administration.
EGCG displays poor bioavailability, and is rapidly metab-
olized in the liver via methylation, glucuronidation, and
sulfation (Lambert et al. 2003; Lu et al. 2003a,b;). EGCG
bioavailability has been increased when it is encapsulated,
or when the reactive hydroxyl groups are protected via
the addition of a peracetate group (Landis-Piwowar et al.
2007; Wu et al. 2013; Li et al. 2014). If the bioavailability
of EGCG can be improved, measuring the levels of EGCG
metabolites could be a useful biomarker for EGCG con-
sumption. The poor bioavailability of EGCG in humans,
however, is a significant obstacle for clinical application
(Nakagawa and Miyazawa 1997; Lin et al. 2007). If large
dosing was required to reach clinically relevant levels, it is
uncertain if high levels of EGCG would lead to increased
EGCG levels in the brain. While few adverse side effects
have been reported during chronic EGCG administration,
it is unknown if a build-up of EGCG in the brain (if pre-
sent) would lead to changes within the brain, or changes
in a specific phenotype.
An Optimal Age for EGCG
Administration to Inhibit Dyrk1a
Activity has not been Defined
A key question pertaining to treatment timing and length
is determining whether a given EGCG treatment will
affect the long-term trajectory of various phenotypes. For
example, if an EGCG treatment that is limited to a partic-
ular prenatal period in which trisomic Dyrk1a is
overexpressed and subsequently rescues phenotypes in
adolescence, this would suggest that the normalization of
excessive Dyrk1a activity during a critical early period is
capable of changing the full trajectory of the trisomic
phenotypes. This raises the question of whether interven-
tions early in development can yield enduring improve-
ment of phenotypes of DS, potentially rescuing brain
development in a manner that persists into adulthood. To
date, only a few studies have administered EGCG pre or
perinatally (Guedj et al. 2009; McElyea et al. 2016). For
example, EGCG treatment at gestational (G)7-G8
improved craniofacial precursor phenotypes in E9.5
embryos, and improved cranial vault structure in these
same mice at 6 weeks of age (McElyea et al. 2016). A
short-term treatment with EGCG (25 mg/kg) from P3–
P15 improved hippocampal neurogenesis at P15 (Stagni
et al. 2016). However, when the animals were evaluated
1 month after the cessation of treatment, there were no
improvements in either hippocampal neurogenesis or per-
formance on the MWM (Stagni et al. 2016). This suggests
that earlier treatment, a second postnatal therapeutic win-
dow, or a continuous treatment may be necessary.
While there is growing interest and support to admin-
ister therapies for DS at earlier stages of development
(Stagni et al. 2015), the majority of studies discussed
administer EGCG postnatally. This is primarily due to the
many unknowns of when Dyrk1a protein expression levels
are elevated in trisomic mice. In addition, there is a lack
of knowledge about the effects of EGCG administration
on the mother or fetus during gestational development.
However, recent studies have started to isolate and iden-
tify the interplay between these two crucial components
of information, in order to develop a rational basis for
the choice of timing and duration of EGCG administra-
tion to trisomic mice. For instance, Dyrk1a mRNA
expression is significantly increased at E9.5 in the first
pharyngeal arch (PA1) and neural tube of Ts65Dn mice,
yet was significantly decreased at E10 in the PA1 of
Ts65Dn mice (Solzak et al. 2013; McElyea et al. 2016).
This temporally and spatially specific expression of
Dyrk1a mRNA levels led to the development of a prenatal
administration of EGCG covering the key period of
increased expression of Dyrk1a to improve the craniofa-
cial abnormalities evident in developing Ts65Dn embryos.
Oral gavage of 200 mg/kg EGCG to pregnant dams twice
daily during gestational days 7–8 improved the PA1 vol-
ume, and number of neural crest cells in E9.5 Ts65Dn
embryos (McElyea et al. 2016). While levels of Dyrk1a
mRNA were not measured at E7–E8, these findings illus-
trate the value of administering treatment based on gene
and/or protein expression during a specific developmental
period in a trisomic mouse. Interestingly, McElyea et al.
2016 also administered a lower dose of EGCG through
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drinking tubes to pregnant Ts65Dn mice (~12 mg/kg/
day), beginning at early gestation through E9.5. In stark
contrast to the 200 mg/kg/day two-day treatment, treat-
ment via the drinking water over the 9.5 days post con-
ception, delivering an average daily dose of EGCG of
12 mg/kg/day, did not improve craniofacial deficits in
E9.5 Ts65Dn mice.
Strategies for developing postnatal EGCG treatment
also need to place primary consideration on factors such
as the dose, route, timing and durations of EGCG treat-
ment, and these choices need to be guided by the tissue-
specific patterns of developmental expression and Dyrk1a
activity. Seemingly small differences in EGCG treatment
approaches can yield discrepant results that are difficult
to reconcile. For example, EGCG treatment via the drink-
ing water (~9 mg/kg/day) for 3 weeks beginning at P24
rescued Ts65Dn skeletal deficits, yet, drinking higher con-
centrations of EGCG (~50 mg/kg/day) for 7 weeks begin-
ning at P24 did not rescue any skeletal or cognitive
deficits (Blazek et al. 2015; Stringer et al. 2017). Further-
more, this dose and length of EGCG treatment signifi-
cantly worsened bone tissue and structural measures in
both Ts65Dn and euploid mice, including decreased cor-
tical and mechanical (strength) parameters associated
with bone. The discrepancies in outcome measures point
to the need to develop rational strategies for therapies tar-
geting Dyrk1a activity, and these new studies need to be
guided first by knowing the tissue-specific patterns of
developmental expression and Dyrk1a activity, then pro-
viding independent confirmation that the doses of EGCG
administered reach the tissues and inhibit Dyrk1a activity.
Conclusions
The interest in developing therapeutics to improve or cor-
rect the deficits caused by Ts21 has exploded over the
past decade. Even within the past few years, there have
been advanced clinical trials, reports in the lay press of
mothers self-administering supplements during preg-
nancy, as well as crowd-funded clinical studies examining
prenatal pharmaceutical treatment for mothers who are
pregnant with a child with DS (Baggot and Baggot 2014;
Bacharach 2016). During these times of growing hope for
therapeutic interventions for individuals with DS that
may improve cognitive and intellectual outcomes, the
responsibility of the research community is to provide
evidence that is objective, verifiable, and replicable.
Two major gaps in knowledge need to be addressed
to establish a mechanistic basis for treatments targeting
excessive Dyrk1a activity using Dyrk1a inhibitors. First,
the temporal and spatial expression of Dyrk1a protein
and kinase activity in trisomic mouse models must be
characterized in greater detail, and altered regulation of
pathways of downstream targets of Dyrk1a needs to be
identified in those tissues during periods of excessive
Dyrk1a activity. A fundamental basis for this approach,
then, is to identify when Dyrk1a is overexpressed in
specific tissues at defined ages in trisomic mice, some
of which may represent sensitive periods of develop-
mental vulnerability that yield long-lasting DS structural
and functional phenotypes. This can then guide efforts
to identify cellular and molecular signaling processes
regulated by Dyrk1a that are disrupted by excessive
Dyrk1a activity. A better understanding of the mecha-
nisms by which Dyrk1a overexpression results in the
neurodevelopmental deficits of DS would provide a
rational basis for therapeutics based on targeted inhibi-
tion of Dyrk1a to produce enduring improvement of
DS phenotypes. Second, the bioavailability, specificity,
and dose-dependent inhibition of Dyrk1a by candidate
therapeutics (including EGCG) must be ascertained for
specific tissues, and correlations between pharmacologi-
cal actions and therapeutic outcomes need to be estab-
lished. Prospects for Dyrk1a inhibition as a molecular
therapy for DS will depend on advances in several key
areas, including: 1) determining specific dosing regimens
and routes of administration that produce dose-depen-
dent changes in drug concentrations in specific tissues
that correlate with concentration-dependent inhibition
of Dyrk1a; and, 2) determining the extent to which
therapeutic efficacy of treatment varies as a function of
developmental timing and duration of treatment and
the temporal profile of tissue-specific inhibition of
Dyrk1a. If EGCG or any other drug targeting trisomic
DYRK1A is to be considered as a rational treatment for
DS phenotypes, it is important that treatment efficacy
be contingent on and optimized for inhibition of
DYRK1A in brain (or other) tissues implicated in the
deficits observed in DS. If confirmed in future research,
molecular therapeutics centered around Dyrk1a inhibi-
tion may provide a means to improve the lives of indi-
viduals with DS.
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